Clinical laboratory results in sarcoidosis patients
| Sarcoidosis radiologic stage (proband ID) . | Gender . | Age, y . | ACE, U/L . | sIL2R CD25, U/mL . | CRP, mg/L . | BAL CD4/CD8 ratio . | BAL lymphocytes, % . |
|---|---|---|---|---|---|---|---|
| III (2062) | M | 66 | 69.3 | 787 | 3.7 | 7.8 | 21 |
| II (2061) | M | 63 | 14.4 | 770 | 7.5 | 5.6 | + |
| I (2065) | M | 53 | 48.5 | 603 | 3.8 | 3.5 | 27 |
| I (2073) | M | 45 | 32 | 577 | 48 | 4.6 | 14 |
| I (2074) | M | 28 | <6.0 | 2109 | 2.3 | 12.6 | 59 |
| II (2078) | M | 35 | <6.0 | 462 | 2.3 | 1.7 | 25 |
| II (2131) | M | 53 | 78.4 | 1373 | 4.8 | 3.2 | 24 |
| Mean | 49 | 41.1 | 954.4 | 10.3 | 5.6 | 28.3 | |
| SD | 13.96 | 23.4 | 588.6 | 16.7 | 3.7 | 15.7 | |
| II (2079) | F | 31 | 71 | 1786 | 1.5 | 6.5 | 50 |
| 0* (2080) | F | 36 | <6.0 | 562 | 1.1 | 2.4 | 10 |
| I (2088) | F | 62 | 34.5 | 898 | 4.1 | 4.3 | 37 |
| II (2094) | F | 50 | <82 | 499 | 2.8 | 4.6 | 19 |
| II (2102) | F | 71 | 80 | 1341 | 1.6 | 11.9 | 20 |
| I (2112) | F | 34 | 66 | 676 | 5.5 | 23.3 | 59 |
| I (2146) | F | 58 | <6.0 | 2660 | 16.4 | 5.9 | 23 |
| Mean | 48.9 | 62.9 | 1203.1 | 4.7 | 8.4 | 31.1 | |
| SD | 15.56 | 19.8 | 791.5 | 5.4 | 7.2 | 18.0 | |
| Normal range | 12.4-81.6 | 223-710 | up to 3 | 0.7-3.5 | <15 |
| Sarcoidosis radiologic stage (proband ID) . | Gender . | Age, y . | ACE, U/L . | sIL2R CD25, U/mL . | CRP, mg/L . | BAL CD4/CD8 ratio . | BAL lymphocytes, % . |
|---|---|---|---|---|---|---|---|
| III (2062) | M | 66 | 69.3 | 787 | 3.7 | 7.8 | 21 |
| II (2061) | M | 63 | 14.4 | 770 | 7.5 | 5.6 | + |
| I (2065) | M | 53 | 48.5 | 603 | 3.8 | 3.5 | 27 |
| I (2073) | M | 45 | 32 | 577 | 48 | 4.6 | 14 |
| I (2074) | M | 28 | <6.0 | 2109 | 2.3 | 12.6 | 59 |
| II (2078) | M | 35 | <6.0 | 462 | 2.3 | 1.7 | 25 |
| II (2131) | M | 53 | 78.4 | 1373 | 4.8 | 3.2 | 24 |
| Mean | 49 | 41.1 | 954.4 | 10.3 | 5.6 | 28.3 | |
| SD | 13.96 | 23.4 | 588.6 | 16.7 | 3.7 | 15.7 | |
| II (2079) | F | 31 | 71 | 1786 | 1.5 | 6.5 | 50 |
| 0* (2080) | F | 36 | <6.0 | 562 | 1.1 | 2.4 | 10 |
| I (2088) | F | 62 | 34.5 | 898 | 4.1 | 4.3 | 37 |
| II (2094) | F | 50 | <82 | 499 | 2.8 | 4.6 | 19 |
| II (2102) | F | 71 | 80 | 1341 | 1.6 | 11.9 | 20 |
| I (2112) | F | 34 | 66 | 676 | 5.5 | 23.3 | 59 |
| I (2146) | F | 58 | <6.0 | 2660 | 16.4 | 5.9 | 23 |
| Mean | 48.9 | 62.9 | 1203.1 | 4.7 | 8.4 | 31.1 | |
| SD | 15.56 | 19.8 | 791.5 | 5.4 | 7.2 | 18.0 | |
| Normal range | 12.4-81.6 | 223-710 | up to 3 | 0.7-3.5 | <15 |
Data in Table 2 refer to the sarcoidosis patients described in Table 1. Histology in all sarcoidosis patients showed noncaseating epitheloid granulomas.
ACE, angiotensin-converting enzyme; BAL, bronchoalveolar lavage; CRP, C-reactive protein; sIL2R, soluble interleukin 2 receptor; +, not done.
Granulomas in bronchial wall.